Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Single-use flexible bronchoscopes compared with reusable bronchoscopes: Positive organizational impact but a costly solution.

Châteauvieux C, Farah L, Guérot E, Wermert D, Pineau J, Prognon P, Borget I, Martelli N.

J Eval Clin Pract. 2018 Mar 23. doi: 10.1111/jep.12904. [Epub ahead of print]

PMID:
29573067
2.

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study.

Marino P, Touzani R, Perrier L, Rouleau E, Kossi DS, Zhaomin Z, Charrier N, Goardon N, Preudhomme C, Durand-Zaleski I, Borget I, Baffert S; NGSEco Group: .

Eur J Hum Genet. 2018 Mar;26(3):314-323. doi: 10.1038/s41431-017-0081-3. Epub 2018 Jan 24.

PMID:
29367707
3.

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.

Le Caer H, Borget I, Corre R, Locher C, Raynaud C, Decroisette C, Berard H, Audigier-Valette C, Dujon C, Auliac JB, Crequit J, Monnet I, Vergnenegre A, Chouaid C.

J Thorac Dis. 2017 Oct;9(10):3747-3754. doi: 10.21037/jtd.2017.09.51.

4.

Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice.

Berdelou A, Borget I, Godbert Y, Nguyen T, Garcia ME, Chougnet CN, Ferru A, Buffet C, Chabre O, Huillard O, Leboulleux S, Schlumberger M.

Thyroid. 2017 Nov 27. doi: 10.1089/thy.2017.0205. [Epub ahead of print]

PMID:
29048237
5.

Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?

Daroles J, Borget I, Suciu V, Mazouni C, Delaloge S, Balleyguier C.

Eur J Cancer. 2017 Nov;85:23-30. doi: 10.1016/j.ejca.2017.08.002. Epub 2017 Sep 4.

PMID:
28881248
6.

Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.

Hadoux J, Terroir M, Leboulleux S, Deschamps F, Al Ghuzlan A, Hescot S, Tselikas L, Borget I, Caramella C, Déandréis D, Goere D, De Baere T, Schlumberger M, Baudin E.

Horm Cancer. 2017 Dec;8(5-6):330-337. doi: 10.1007/s12672-017-0303-8. Epub 2017 Jul 26.

PMID:
28748315
7.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC.

Eur J Cancer. 2017 Sep;83:185-193. doi: 10.1016/j.ejca.2017.05.016. Epub 2017 Jul 22.

PMID:
28743036
8.

Existing reporting guidelines for clinical trials are not completely relevant for implantable medical devices: a systematic review.

Motte AF, Diallo S, van den Brink H, Châteauvieux C, Serrano C, Naud C, Steelandt J, Alsac JM, Aubry P, Cour F, Pellerin O, Pineau J, Prognon P, Borget I, Bonan B, Martelli N.

J Clin Epidemiol. 2017 Nov;91:111-120. doi: 10.1016/j.jclinepi.2017.07.005. Epub 2017 Jul 18. Review.

PMID:
28728922
9.

HARMONIZING HEALTH TECHNOLOGY ASSESSMENT PRACTICES IN UNIVERSITY HOSPITALS: TO WHAT EXTENT IS THE MINI-HTA MODEL SUITABLE IN THE FRENCH CONTEXT?

Martelli N, Devaux C, van den Brink H, Billaux M, Pineau J, Prognon P, Borget I.

Int J Technol Assess Health Care. 2017 Jan;33(2):307-314. doi: 10.1017/S0266462317000393. Epub 2017 Jun 5.

PMID:
28580892
10.

HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT FOR THE ADOPTION OF INNOVATIVE MEDICAL DEVICES WITHIN FRENCH HOSPITALS: OPPORTUNITIES AND CHALLENGES FOR INDUSTRY.

Dutot C, Mercier G, Borget I, de Sauvebeuf C, Martelli N.

Int J Technol Assess Health Care. 2017 Jan;33(2):297-302. doi: 10.1017/S0266462317000368. Epub 2017 Jun 5.

PMID:
28578711
11.

Assessment of the novel online delineation workshop dummy run approach using FALCON within a European multicentre trial in cervical cancer (RAIDs).

Rivin Del Campo E, Rivera S, Martínez-Paredes M, Hupé P, Slocker Escarpa A, Borget I, Mazeron R, Scholl S, Palacios Eito A, Haie-Meder C, Chargari C, Deutsch E.

Radiother Oncol. 2017 Jul;124(1):130-138. doi: 10.1016/j.radonc.2017.05.008. Epub 2017 May 19.

PMID:
28532608
12.

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.

Pailler E, Oulhen M, Borget I, Remon J, Ross K, Auger N, Billiot F, Ngo Camus M, Commo F, Lindsay CR, Planchard D, Soria JC, Besse B, Farace F.

Cancer Res. 2017 May 1;77(9):2222-2230. doi: 10.1158/0008-5472.CAN-16-3072.

PMID:
28461563
13.

Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors.

Lamartina L, Borget I, Mirghani H, Al Ghuzlan A, Berdelou A, Bidault F, Deandreis D, Baudin E, Travagli JP, Schlumberger M, Hartl DM, Leboulleux S.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):1020-1031. doi: 10.1210/jc.2016-3284.

PMID:
28359102
14.

Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test.

Mirghani H, Casiraghi O, Guerlain J, Amen F, He MX, Ma XJ, Luo Y, Mourareau C, Drusch F, Lakdhar AB, Melkane A, St Guily L, Badoual C, Scoazec JY, Borget I, Aupérin A, Dalstein V, Vielh P.

Oral Oncol. 2016 Nov;62:101-108. doi: 10.1016/j.oraloncology.2016.10.009. Epub 2016 Oct 21.

PMID:
27865361
15.

The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer.

Terroir M, Borget I, Bidault F, Ricard M, Deschamps F, Hartl D, Tselikas L, Dercle L, Lumbroso J, Baudin E, Berdelou A, Deandreis D, Schlumberger M, Leboulleux S.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):638-646. doi: 10.1007/s00259-016-3551-x. Epub 2016 Oct 29.

PMID:
27796544
16.

The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic.

Delaloge S, Bonastre J, Borget I, Garbay JR, Fontenay R, Boinon D, Saghatchian M, Mathieu MC, Mazouni C, Rivera S, Uzan C, André F, Dromain C, Boyer B, Pistilli B, Azoulay S, Rimareix F, Bayou el-H, Sarfati B, Caron H, Ghouadni A, Leymarie N, Canale S, Mons M, Arfi-Rouche J, Arnedos M, Suciu V, Vielh P, Balleyguier C.

Eur J Cancer. 2016 Oct;66:131-7. doi: 10.1016/j.ejca.2016.06.021. Epub 2016 Aug 26.

PMID:
27569041
17.

[Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database].

Freyer G, Scotte F, Borget I, Bruyas A, Vainchtock A, Chouaid C.

Bull Cancer. 2016 Jun;103(6):552-60. doi: 10.1016/j.bulcan.2016.03.012. Epub 2016 May 24. French.

PMID:
27233367
18.

Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer.

Lamartina L, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, Al Ghuzlan A, Hartl D, Blanchard P, Terroir M, Deandreis D, Schlumberger M, Baudin E, Leboulleux S.

J Clin Endocrinol Metab. 2016 Jul;101(7):2733-41. doi: 10.1210/jc.2015-4391. Epub 2016 Apr 15.

PMID:
27082933
19.

Anatomic Variability of the Upper Mediastinal Lymph Node Level VII.

Hartl DM, Breuskin I, Mirghani H, Berdelou A, Déandréis D, Pottier E, Borget I, Schlumberger M, Leboulleux S.

World J Surg. 2016 Aug;40(8):1899-903. doi: 10.1007/s00268-016-3505-2.

PMID:
27075985
20.

Advantages and disadvantages of 3-dimensional printing in surgery: A systematic review.

Martelli N, Serrano C, van den Brink H, Pineau J, Prognon P, Borget I, El Batti S.

Surgery. 2016 Jun;159(6):1485-1500. doi: 10.1016/j.surg.2015.12.017. Epub 2016 Jan 30. Review.

PMID:
26832986
21.

French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends.

Chouaid C, Borget I, Braun E, Bazil ML, Schaetz D, Rémuzat C, Toumi M.

Target Oncol. 2016 Aug;11(4):515-34. doi: 10.1007/s11523-015-0411-8.

22.

New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues.

Martelli N, van den Brink H, Borget I.

Value Health. 2016 Jan;19(1):17-9. doi: 10.1016/j.jval.2015.10.006. Epub 2015 Nov 21.

23.

Combining multi-criteria decision analysis and mini-health technology assessment: A funding decision-support tool for medical devices in a university hospital setting.

Martelli N, Hansen P, van den Brink H, Boudard A, Cordonnier AL, Devaux C, Pineau J, Prognon P, Borget I.

J Biomed Inform. 2016 Feb;59:201-8. doi: 10.1016/j.jbi.2015.12.002. Epub 2015 Dec 15.

24.

A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty.

Martelli N, Devaux C, van den Brink H, Pineau J, Prognon P, Borget I.

PLoS One. 2015 Dec 10;10(12):e0144892. doi: 10.1371/journal.pone.0144892. eCollection 2015. Review.

25.

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).

Raynaud C, Greillier L, Mazieres J, Monnet I, Mastroianni B, Robinet G, Fraboulet G, Dixmier A, Berard H, Lamy R, Letreut J, Lena H, Oliviero G, Botta S, Vergnenegre A, Borget I, Chouaid C.

BMC Cancer. 2015 Nov 6;15:857. doi: 10.1186/s12885-015-1881-x.

26.

The Use of Indirect Comparisons in Medicines Evaluation for their Access To Reimbursement by the Has.

Guichard M, D'Andon A, Rumeau Pichon C, Borget I.

Value Health. 2015 Nov;18(7):A719. doi: 10.1016/j.jval.2015.09.2724. Epub 2015 Oct 20. No abstract available.

27.

French Health Technology Assessment Of Antineoplastic Drugs Indicated In The Treatment Of Solid Tumours: Perspective For Future Trends.

Chouaid C, Borget I, Braun E, Bazil M, Schaetz D, Rémuzat C, Toumi M.

Value Health. 2015 Nov;18(7):A489. doi: 10.1016/j.jval.2015.09.1353. Epub 2015 Oct 20. No abstract available.

28.

Cost Of Genome Analysis: The Sanger Sequencing Method.

Perrier L, Heinz D, Baffert S, Zou Z, Durand Zaleski I, Rouleau E, Wang Q, Haddad V, Bringuier P, Merlio J, Caumont C, Lacroix L, Marino P, Borget I.

Value Health. 2015 Nov;18(7):A353. doi: 10.1016/j.jval.2015.09.654. Epub 2015 Oct 20. No abstract available.

29.

Dosimetric Effects of the Interfraction Variations during Whole Breast Radiotherapy: A Prospective Study.

Jacob J, Heymann S, Borget I, Dumas I, Riahi E, Maroun P, Ezra P, Roberti E, Rivera S, Deutsch E, Bourgier C.

Front Oncol. 2015 Sep 16;5:199. doi: 10.3389/fonc.2015.00199. eCollection 2015.

30.

Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.

Libé R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M, Quinkler M, Chabre O, Bala M, Tabarin A, Beuschlein F, Vezzosi D, Deutschbein T, Borson-Chazot F, Hermsen I, Stell A, Fottner C, Leboulleux S, Hahner S, Mannelli M, Berruti A, Haak H, Terzolo M, Fassnacht M, Baudin E; ENSAT network.

Ann Oncol. 2015 Oct;26(10):2119-25. doi: 10.1093/annonc/mdv329.

31.

Innovative medical devices and hospital decision making: a study comparing the views of hospital pharmacists and physicians.

Billaux M, Borget I, Prognon P, Pineau J, Martelli N.

Aust Health Rev. 2016 Jun;40(3):257-261. doi: 10.1071/AH15039.

PMID:
26342894
32.

Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial.

Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Kelly A, Toubert ME, Leboulleux S, Journeau F, Benhamou E, Schlumberger M.

J Clin Oncol. 2015 Sep 10;33(26):2885-92. doi: 10.1200/JCO.2015.61.6722. Epub 2015 Aug 3.

PMID:
26240230
33.

INTRODUCTION OF INNOVATIVE MEDICAL DEVICES AT FRENCH UNIVERSITY HOSPITALS: AN OVERVIEW OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT INITIATIVES.

Martelli N, Billaux M, Borget I, Pineau J, Prognon P, van den Brink H.

Int J Technol Assess Health Care. 2015 Jan;31(1-2):12-8. doi: 10.1017/S0266462315000057. Epub 2015 May 20.

PMID:
25991072
34.

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.

Pailler E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, Ngo-Camus M, Planchard D, Soria JC, Besse B, Farace F.

Ann Oncol. 2015 Jul;26(7):1408-15. doi: 10.1093/annonc/mdv165. Epub 2015 Apr 6.

35.

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.

Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A, Loriot Y, Duvillard P, Chougnet CN, Déandréis D, Schlumberger M, Borget I, Ducreux M, Baudin E.

Endocr Relat Cancer. 2015 Jun;22(3):289-98. doi: 10.1530/ERC-15-0075. Epub 2015 Mar 13.

36.

The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France.

Scotte F, Martelli N, Vainchtock A, Borget I.

Adv Ther. 2015 Feb;32(2):138-47. doi: 10.1007/s12325-015-0187-3. Epub 2015 Feb 26.

PMID:
25716549
37.

Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-up.

Lepoutre-Lussey C, Caramella C, Bidault F, Déandreis D, Berdelou A, Al Ghuzlan A, Hartl D, Borget I, Gimenez-Roqueplo AP, Dumont F, Deschamps F, Nascimento C, Lumbroso J, Guillaud Bataille M, Schlumberger M, Baudin E, Leboulleux S.

Eur J Nucl Med Mol Imaging. 2015 May;42(6):868-76. doi: 10.1007/s00259-015-3003-z. Epub 2015 Feb 13.

PMID:
25676472
38.

Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.

Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey C, Mirghani H, Baudin E, Schlumberger M, Leboulleux S.

Thyroid. 2015 Apr;25(4):437-44. doi: 10.1089/thy.2014.0320. Epub 2015 Mar 16.

PMID:
25633259
39.

Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.

Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M.

Thyroid. 2015 Apr;25(4):386-91. doi: 10.1089/thy.2014.0361. Epub 2015 Feb 18.

PMID:
25627619
40.

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review.

Chouaïd C, Crequit P, Borget I, Vergnenegre A.

Clinicoecon Outcomes Res. 2014 Dec 15;7:9-15. doi: 10.2147/CEOR.S43328. eCollection 2015. Review.

41.

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.

Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C; IFCT-GFPC investigators.

BMC Cancer. 2014 Dec 15;14:953. doi: 10.1186/1471-2407-14-953.

42.

[Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].

Borget I, Antoun S, Chachaty E, Gachot B, Alibay A, Di Palma M, Merad M.

Bull Cancer. 2014 Oct;101(10):925-31. doi: 10.1684/bdc.2014.1958. French.

PMID:
25373692
43.

Hospital Cost of Thromboembolic Events in Breast or Prostate Cancer Patients.

Scotte F, Martelli N, Vainchtock A, Borget I.

Value Health. 2014 Nov;17(7):A625. doi: 10.1016/j.jval.2014.08.2224. Epub 2014 Oct 26. No abstract available.

44.

Companion Diagnostics-Targeted Therapies Pairings Model-Based Economic Evaluation: Reflection On A General Modeling Framework And Key Methodological Points.

Marty R, Roze S, Tisseau A, Borget I, Chouaid C.

Value Health. 2014 Nov;17(7):A565. doi: 10.1016/j.jval.2014.08.1878. Epub 2014 Oct 26. No abstract available.

45.

Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?

Chouaid C, Borget I, Vergnenegre A.

J Clin Oncol. 2014 Nov 1;32(31):3577. doi: 10.1200/JCO.2014.56.2157. Epub 2014 Sep 8. No abstract available.

PMID:
25199755
46.

Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review.

Mamelle E, Borget I, Leboulleux S, Mirghani H, Suárez C, Pellitteri PK, Shaha AR, Hamoir M, Robbins KT, Khafif A, Rodrigo JP, Silver CE, Rinaldo A, Ferlito A, Hartl DM.

Eur Arch Otorhinolaryngol. 2015 Jul;272(7):1577-86. doi: 10.1007/s00405-014-3104-5. Epub 2014 Jun 11. Review.

47.

Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients.

Levy A, Borget I, Bahri M, Arnedos M, Rivin E, Vielh P, Balleyguier C, Rimareix F, Bourgier C.

Breast J. 2014 Jul-Aug;20(4):381-7. doi: 10.1111/tbj.12277. Epub 2014 Jun 2.

PMID:
24890310
48.

SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.

Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Déandreis D, Borget I, Loriot C, Chougnet C, Letouzé E, Young J, Amar L, Bertherat J, Libé R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E.

Int J Cancer. 2014 Dec 1;135(11):2711-20. doi: 10.1002/ijc.28913. Epub 2014 May 5.

49.

Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia.

Desplanques PY, Burlacu R, Poinsignon V, Boussion H, Borget I, Wyplosz B, de Botton S, Billaud E, Chachaty E, Gachot B, Netzer F, Micol JB.

Med Mal Infect. 2014 Apr;44(4):174-9. doi: 10.1016/j.medmal.2014.02.005. Epub 2014 Mar 19.

PMID:
24656841
50.

Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.

Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, Do Cao C, Chougnet CN, Leboulleux S, Baudin E, Schlumberger M, de la Fouchardière C.

Eur J Endocrinol. 2014 Mar 8;170(4):575-82. doi: 10.1530/EJE-13-0825. Print 2014 Apr.

Supplemental Content

Loading ...
Support Center